NASDAQ: LITSLite Strategy Inc Stock
$0.74+0.00 (+0%)
Updated Jun 12, 2026
LITS Price
$0.74
Fair Value Price
N/A
Market Cap
$25.21M
52 Week Low
$0.69
52 Week High
$9.00
P/E
-0.37x
P/B
0.44x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$60.82M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.02
Operating Cash Flow
-$10M
Beta
0.87
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LITS Overview
Lite Strategy, Inc. functions as a clinical-stage pharmaceutical firm, concentrating its efforts on creating innovative and distinct therapeutic solutions for cancer patients. This entity, which was previously known as MEI Pharma, Inc., officially changed its designation to Lite Strategy, Inc. in September 2025. The company was established in 2000 and has its principal operations located in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LITS's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LITS
Ranked#403 of 463
Ranked#403 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.56 | A | |
| $53.13 | A | |
| $15.82 | A |
Be the first to know about important LITS news, forecast changes, insider trades & much more!
LITS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LITS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LITS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LITS is good value based on its book value relative to its share price (0.44x), compared to the US Biotechnology industry average (4.85x)
P/B vs Industry Valuation
LITS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LITS due diligence checks available for Premium users.
Valuation
LITS fair value
Fair Value of LITS stock based on Discounted Cash Flow (DCF)
Price
$0.74
Fair Value
$2.70
Undervalued by
72.62%
LITS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LITS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.37x
Industry
16.53x
Market
14.15x
LITS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.44x
Industry
4.85x
LITS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LITS's financial health
Profit margin
Revenue
$0.0
Net Income
-$23.7M
Profit Margin
0%
LITS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$57.8M
Liabilities
$952.0k
Debt to equity
0.02
LITS's short-term assets ($10.98M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LITS's short-term assets ($10.98M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LITS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LITS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.5M
Investing
$2.1M
Financing
-$1.8M
LITS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LITS vs Biotech Stocks
Lite Strategy Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.